In prostate cancer, wild-type and mutant delta-catenin both exhibited pro-oncogenic and tumor-suppressive functions; that study found a protein truncation, caused by a nonsense mutation of delta-catenin, mainly occurring in the cytoplasm, promoted carcinoma progression via various pathways (Li et al., 2020). This evidence concerns the gene CTNND2 and prostate cancer.